References
- Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA Jr., Gern J, Heymann PW, Martinez FD, Mauger D, Teague WG, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol. 2012;129(3 Suppl):S34–S48. doi:https://doi.org/10.1016/j.jaci.2011.12.983.
- Global Initiative for Asthma [GINA]. Global strategy for asthma management and prevention (2021 report). 2021. Available from: https://ginasthma.org/gina-reports/.
- Papaioannou AI, Kostikas K, Zervas E, Kolilekas L, Papiris S, Gaga M. Control of asthma in real life: still a valuable goal? Eur Respir Rev. 2015;24(136):361–369. doi:https://doi.org/10.1183/16000617.00001615.
- Pavord ID, Mathieson N, Scowcroft A, Pedersini R, Isherwood G, Price D. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting beta2-agonists in the United Kingdom: a cross-sectional analysis. NPJ Prim Care Respir Med. 2017;27(1):17. doi:https://doi.org/10.1038/s41533-017-0014-1.
- FitzGerald JM, Hamelmann E, Kerstjens HAM, Buhl R. Asthma exacerbations and worsenings in patients aged 1-75 years with add-on tiotropium treatment. NPJ Prim Care Respir Med. 2020;30(1):38. doi:https://doi.org/10.1038/s41533-020-00193-w.
- Peters SP, Jones CA, Haselkorn T, Mink DR, Valacer DJ, Weiss ST. Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol. 2007;119(6):1454–1461. doi:https://doi.org/10.1016/j.jaci.2007.03.022.
- Oppenheimer J, Slade DJ, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Lima R, Molfino NA, Averell CM. Real-world evidence: patient views on asthma in respiratory specialist clinics in America. Ann Allergy Asthma Immunol. 2021;126(4):385–393.e2. doi:https://doi.org/10.1016/j.anai.2020.12.015.
- Sullivan PW, Ghushchyan VH, Campbell JD, Globe G, Bender B, Magid DJ. Measuring the cost of poor asthma control and exacerbations. J Asthma. 2017;54(1):24–31. doi:https://doi.org/10.1080/02770903.2016.1194430.
- Mungan D, Aydin O, Mahboub B, Albader M, Tarraf H, Doble A, Lahlou A, Tariq L, Aziz F, El Hasnaoui A. Burden of disease associated with asthma among the adult general population of five Middle Eastern countries: Results of the SNAPSHOT program. Respir Med. 2018;139:55–64. doi:https://doi.org/10.1016/j.rmed.2018.03.030.
- Reddel HK, Taylor DR, Bateman ED, Boulet L-P, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59–99. doi:https://doi.org/10.1164/rccm.200801-060ST.
- Virchow JC, Backer V, de Blay F, Kuna P, Ljørring C, Prieto JL, Villesen HH. Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement. Respir Med. 2015;109(5):547–556. doi:https://doi.org/10.1016/j.rmed.2015.01.012.
- National Asthma Education Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–S138. doi:https://doi.org/10.1016/j.jaci.2007.09.043.
- Cloutier MM, Baptist AP, Blake KV, Brooks EG, Bryant-Stephens T, DiMango E, Dixon AE, Elward KS, Hartert T, Krishnan JA, Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) and National Asthma Education and Prevention Program Coordinating Committee (NEPPCC), et al. 2020 Focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. doi:https://doi.org/10.1016/j.jaci.2020.10.003.
- GlaxoSmithKline (Ireland) Limited. Summary of product characteristics. Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed. 2021.
- GlaxoSmithKline. Highlights of prescribing information. BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder), for oral inhalation use. 2019.
- Bateman ED, O’Byrne PM, Busse WW, Lötvall J, Bleecker ER, Andersen L, Jacques L, Frith L, Lim J, Woodcock A. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014;69(4):312–319. doi:https://doi.org/10.1136/thoraxjnl-2013-203600.
- Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. The Lancet. 2017;390(10109):2247–2255. doi:https://doi.org/10.1016/S0140-6736(17)32397-8.
- Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. J Asthma. 2019;56(7):748–757. doi:https://doi.org/10.1080/02770903.2018.1490751.
- World Health Organization. ICD-10: international statistical classification of diseases and related health problems: tenth revision. World Health Organization. 2004.
- Global Initiative for Asthma [GINA]. Global strategy for asthma management and prevention (2018 report). 2018. Available from: https://ginasthma.org/gina-reports/.
- Fischer F, Lange K, Klose K, Greiner W, Kraemer A. Barriers and strategies in guideline implementation-a scoping review. Healthcare (Basel). 2016;4(3):36. doi:https://doi.org/10.3390/healthcare4030036.
- Nwaru BI, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020;55(4):1901872. doi:https://doi.org/10.1183/13993003.01872-2019.
- Briggs A, Nasser S, Hammerby E, Buchs S, Virchow JC. The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data. J Patient Rep Outcomes. 2021;5(1):6. doi:https://doi.org/10.1186/s41687-020-00274-x.
- Parimi M, Svedsater H, Ann Q, Gokhale M, Gray CM, Hinds D, Nixon M, Boxall N. Persistence and adherence to ICS/LABA drugs in UK patients with asthma: a retrospective new-user cohort study. Adv Ther. 2020;37(6):2916–2931. doi:https://doi.org/10.1007/s12325-020-01344-8.
- Averell CM, Stanford RH, Laliberté F, Wu JW, Germain G, Duh MS. Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs. J Asthma. 2021;58(1):102–111. doi:https://doi.org/10.1080/02770903.2019.1663429.
- Stanford RH, Averell C, Parker ED, Blauer-Peterson C, Reinsch TK, Buikema AR. Assessment of adherence and asthma medication ratio for a once-daily and twice-daily inhaled corticosteroid/long-acting beta-agonist for asthma. J Allergy Clin Immunol Pract. 2019;7(5):1488–1496 e7. doi:https://doi.org/10.1016/j.jaip.2018.12.021.
- Delea TE, Stanford RH, Hagiwara M, Stempel DA. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Curr Med Res Opin. 2008;24(12):3435–3442. doi:https://doi.org/10.1185/03007990802557344.
- Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396–407. doi:https://doi.org/10.1183/09031936.00075614.